Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2022

View Archived Issues

New DNA-dependent protein kinase inhibitors divulged by Shouyao Holdings

Vasopressin V1A receptor antagonists discovered at Roche

Medshine Discovery identifies SOS1/Gly12Cys mutant GTPase KRAS interaction inhibitors

Betta Pharmaceuticals describes new PTPN11 inhibitors

Merck KGaA, Cancer Research Technology present YAP1/TEAD interaction inhibitors

Akouos presents preclinical data on anti-VEGF AAVAnc80 vector for vestibular schwannoma

ADAM8 drives severity in acute respiratory distress syndrome trough neutrophil migration

Increasing catalase activity reverses estrogen-mediated aging

Aquinnah and Roche collaborate in ALS and neurodegenerative diseases

Alamar and SciNeuro to discover and develop novel therapeutic antibodies for neurological diseases

NTS-104 reduces critical neuroinflammatory signaling in rat embolic stroke model

Persistent Ebolavirus in brain seeds relapses

NIBIOHN and Shionogi announce discovery of novel antiviral antibody for SARS-CoV-2

Memo Therapeutics to advance lead programs

YTHDF1 is involved in renal fibrosis through upregulation of YAP

Financing at Third Harmonic Bio to support development of oral KIT inhibitor THB-001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...